|
|
||||||||
Ann Thorac Surg 2000;70:191-196
© 2000 The Society of Thoracic Surgeons
a Division of Cardiothoracic Surgery, Tisch Hospital, New York University School of Medicine, New York, New York, USA
b Division of Pediatric Cardiology, Tisch Hospital, New York University School of Medicine, New York, New York, USA
Address reprint requests to Dr Grossi, Department of Surgery, New York University Medical Center, 530 First Ave, Suite 9V, New York, NY 10016
e-mail: grossi{at}cv.med.nyu.edu
Background. Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass in adult patients; however, little is known about its effects in the pediatric population. Two studies were performed to assess this technologys impact on inflammation and clinical outcomes.
Methods. In a pilot study, complement and interleukins were measured in 19 patients who had either uncoated cardiopulmonary bypass circuits or heparin-bonded circuits. Subsequently, 23 additional patients were studied in a randomized fashion. Respiratory function and blood product utilization were recorded.
Results. In the pilot study, heparin-bonded circuit patients had less complement 3a (p < 0.001) and interleukin-8 (p < 0.05) compared with uncoated cardiopulmonary bypass circuit patients. The randomized study revealed that the heparin-bonded circuit was associated with reduced complement 3a (p = 0.02). Multiple variable analysis revealed that the following postoperative variables were increased with bypass time (p = 0.01) and diminished with heparin-bonded circuits: interleukins (p = 0.01), peak airway pressures (p = 0.05), and prothrombin time (p = 0.03).
Conclusions. Heparin-bonded circuits significantly reduce cytokines and complement during cardiopulmonary bypass and lower interleukin levels postbypass; they were also associated with improved pulmonary and coagulation function. Heparin-bonded circuits ameliorate the systemic inflammatory response in pediatric patients from cardiopulmonary bypass.
This article has been cited by other articles:
![]() |
G. Furlanetto, C. H Passerino, R. Siegel, D. T Chueng, S. Levitsky, and I. S J Casagrande Biointegration and Growth of Porcine Valved Pulmonary Conduits in a Sheep Model Asian Cardiovasc Thorac Ann, August 1, 2009; 17(4): 350 - 356. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. S. Murphy, E. A. Hessel II, and R. C. Groom Optimal Perfusion During Cardiopulmonary Bypass: An Evidence-Based Approach Anesth. Analg., May 1, 2009; 108(5): 1394 - 1417. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Eggum, T. Ueland, T. E. Mollnes, V. Videm, P. Aukrust, A. E. Fiane, and H. L. Lindberg Effect of Perfusion Temperature on the Inflammatory Response During Pediatric Cardiac Surgery Ann. Thorac. Surg., February 1, 2008; 85(2): 611 - 617. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Mangoush, S. Purkayastha, S. Haj-Yahia, J. Kinross, M. Hayward, F. Bartolozzi, A. Darzi, and T. Athanasiou Heparin-bonded circuits versus nonheparin-bonded circuits: an evaluation of their effect on clinical outcomes Eur. J. Cardiothorac. Surg., June 1, 2007; 31(6): 1058 - 1069. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Jessen Pro: Heparin-Coated Circuits Should be Used for Cardiopulmonary Bypass Anesth. Analg., December 1, 2006; 103(6): 1365 - 1369. [Full Text] [PDF] |
||||
![]() |
R. Taneja and D. C. Cheng Con: Heparin-Bonded Cardiopulmonary Bypass Circuits Should Be Routine for All Cardiac Surgical Procedures Anesth. Analg., December 1, 2006; 103(6): 1370 - 1372. [Full Text] [PDF] |
||||
![]() |
S W Sutton, A N Patel, V A Chase, L A Schmidt, E K Hunley, L W Yancey, R F Hebeler, E H Cheung, A C Henry III, T P Meyers, et al. Clinical benefits of continuous leukocyte filtration during cardiopulmonary bypass in patients undergoing valvular repair or replacement Perfusion, January 1, 2005; 20(1): 21 - 29. [Abstract] [PDF] |
||||
![]() |
M. J. Scallan Cerebral injury during paediatric heart surgery: perfusion issues Perfusion, July 1, 2004; 19(4): 221 - 228. [Abstract] [PDF] |
||||
![]() |
A. Boning, J. Scheewe, T. Ivers, C. Friedrich, J. Stieh, S. Freitag, and J. T. Cremer Phosphorylcholine or heparin coating for pediatric extracorporeal circulation causes similar biologic effects in neonates and infants J. Thorac. Cardiovasc. Surg., May 1, 2004; 127(5): 1458 - 1465. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Eisses, K. Seidel, G. S. Aldea, and W. L. Chandler Reducing Hemostatic Activation During Cardiopulmonary Bypass: A Combined Approach Anesth. Analg., May 1, 2004; 98(5): 1208 - 1216. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Jensen, S. Andreasson, A. Bengtsson, H. Berggren, R. Ekroth, L. E. Larsson, and J. Ouchterlony Changes in hemostasis during pediatric heart surgery: impact of a biocompatible heparin-coated perfusion system Ann. Thorac. Surg., March 1, 2004; 77(3): 962 - 967. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Jensen, S. Andreasson, A. Bengtsson, H. Berggren, R. Ekroth, L. Lindholm, and J. Ouchterlony Influence of two different perfusion systems on inflammatory response in pediatric heart surgery Ann. Thorac. Surg., March 1, 2003; 75(3): 919 - 925. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. R. Stephenson Jr and J. L. Myers Pediatric cardiopulmonary bypass Ann. Thorac. Surg., December 1, 2001; 72(6): 2176 - 2177. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |